| 刘 慧,王 娜,王 佳.治疗前RhoBTB3表达对新发非M3型急性髓系白血病患者生存的预测分析[J].肿瘤学杂志,2025,31(2):144-151. |
| 治疗前RhoBTB3表达对新发非M3型急性髓系白血病患者生存的预测分析 |
| Pretreatment RhoBTB3 Expression Predicts Survival Outcomes in Patients with Newly-Onset Non-M3 Acute Myeloid Leukemia |
| 投稿时间：2024-07-11 |
| DOI：10.11735/j.issn.1671-170X.2025.02.B009 |
|
 |
| 中文关键词: 急性髓系白血病 RhoBTB3 总生存期 无复发生存期 |
| 英文关键词:acute myeloid leukemia RhoBTB3 overall survival relapse-free survival |
| 基金项目:陕西省医学科学研究重点课题（20JM1142） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘 要：［目的］探讨治疗前RhoBTB3表达对新发非M3型急性髓系白血病（acute myeloid leukemia，AML）患者生存结局的预测作用。［方法］ 基于GEPIA数据库分析了RhoBTB3在AML患者中的表达模式，并利用TCGA和GEO数据集进行生存分析。收集2017年1月至2020年2月在西安交通大学医学部附属三二〇一医院接受治疗的新发非M3型AML患者共83例，通过RT-qPCR验证RhoBTB3在AML骨髓和健康者正常骨髓中的差异表达。采用受试者工作特征（receiver operating characteristic，ROC）曲线分析确定RhoBTB3的诊断价值。行Kaplan-Meier生存率分析和多变量Cox分析，评估RhoBTB3在不同治疗方案的非M3型AML患者中的预后价值。［结果］ GEPIA数据库中，与健康人群样本相比，AML骨髓中RhoBTB3 mRNA表达水平显著降低（P=0.026）。TCGA和GEO数据集的生存曲线分析初步表明，RhoBTB3与非M3 型AML患者的总生存期有关（P＜0.05）。qRT-PCR结果显示，与健康对照组［0.93（0.64，1.24）］相比，非M3型AML患者RhoBTB3表达水平显著下调［0.21（0.03，0.62）］（P＜0.001）。RhoBTB3在诊断AML患者与健康对照组时的ROC曲线下面积为0.839，特异度为100.0%。在未接受异基因造血干细胞移植（hematopoietic stem cell transplantation，HSCT）患者中，RhoBTB3＞0.21的患者表现出相对较长的总生存期和无复发生存期，多变量Cox分析显示RhoBTB3表达较高是该类患者独立的有利预后因素（P＜0.05）。然而，在HSCT患者中，RhoBTB3≤0.21亚组和＞0.21亚组之间的总生存期和无复发生存期均无显著性差异（P＞0.05）。［结论］ RhoBTB3是非M3型AML的预后标志物，可能有助于患者个体化治疗方案选择。 |
| 英文摘要: |
| Abstract： ［Objective］ To investigate the association of RhoBTB3 expression with survival outcome of patients with newly-onset non-M3 acute myeloid leukemia (AML). ［Methods］ The expression pattern of RhoBTB3 in AML patients was obtained from GEPIA database， and survival of AML patients were collected from TCGA and GEO datasets. Eighty three patients with newly diagnosed non-M3 AML treated in 3201 Hospital of Xi’an Jiaotong University Health Science Center from January 2017 to February 2020 were included in the study. The differential expression of RhoBTB3 in AML bone marrow and normal bone marrow was detected by RT-qPCR. Receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic value of RhoBTB3. Kaplan-Meier survival analysis and multivariate Cox analysis were performed to evaluate the prognostic value of RhoBTB3 in patients with non-M3 AML with different treatment regimenes. ［Results］ GEPIA database showed that RhoBTB3 mRNA expression level in AML bone marrow was significantly decreased compared with the healthy subjects (P=0.026). The TCGA and GEO datasets showed that RhoBTB3 was significantly associated with overall survival (OS) prognosis in non-M3 AML patients (P＜0.05). qRT-PCR result showed that compared with the control group ［0.93 (0.64， 1.24)］， RhoBTB3 expression level in non-M3 AML patients was significantly down-regulated ［0.21 (0.03， 0.62)， P＜0.001］. The area under ROC curve (AUC) of RhoBTB3 for diagnosis of M3 AML was 0.839， with a specificity of 100.0%. In AML patients with RhoBTB3＞0.21， who did not receive allogeneic hematopoietic stem cell transplantation (HSCT)， showed a relatively longer OS and relapse-free survival (RFS) time； and multivariate Cox analysis showed that high RhoBTB3 expression was an independent favorable prognostic factor (P＜0.05). However， in patients with HSCT， no significant difference in OS and EFS was found between patients with RhoBTB3 ≤0.21 and those ＞0.21 (P＞0.05). ［Conclusion］ RhoBTB3 is a prognostic marker for non-M3 AML and may contribute to individualized treatment options for patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |